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OBJECTIVES: Patients at goal low-density lipoprotein choles-
terol (LDL-C) levels continue to have cardiovascular disease
(CVD) risk, especially those who also have abnormal high-
density lipoprotein cholesterol (HDL-C) and/or triglyceride (TG)
levels. Despite evidence on the importance of managing LDL-C,
HDL-C and TG, controversy resides over whether to continue
lowering LDL-C or to target HDL-C and TG. Niaspan® and
Zetia® are two commonly prescribed alternatives for add-on
therapy to statins, but information is lacking on the economic
impact of add-on therapy. As such, an analysis was conducted to
estimate the cost-effectiveness of Niaspan versus Zetia as add-on
therapy in high-risk statin-treated patients with a history of
CVD. METHODS: A model was developed to predict CVD
events (myocardial infarction, stroke, angina) and costs in a
high-risk US managed care population receiving on-going statin
(branded and generic) therapy over ﬁve years. Risk for CVD
events was predicted using equations from the Framingham
Heart Study. CVD event and follow-up costs were from an inpa-
tient administrative claims database and the published literature,
respectively. Drug costs were based on wholesale acquisition
costs (WAC); daily WAC for Niaspan was weighted to reﬂect a
12-week dose-titration period. The efﬁcacy of each drug combi-
nation was derived based on product labeling and adjusted to
reﬂect mean days on therapy. RESULTS: The addition of
Niaspan resulted in up to a 20% reduction in CVD events versus
Zetia. For incremental cost effectiveness per CVD event avoided
when added to pravastatin or Lipitor®, Niaspan dominated
Zetia (i.e., less costly and more effective). In lovastatin, simvas-
tatin, or Crestor® patients, the addition of Niaspan relative
to Zetia was highly cost-effective with incremental cost-
effectiveness ratios of $2,258, $18,041, and $5,463, respectively.
CONCLUSIONS: When added to pravastatin or Lipitor,
Niaspan dominates Zetia and is highly-cost effective when com-
bined with lovastatin, simvastatin, or Crestor in reducing CVD
events.
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OBJECTIVES: Statin-treated patients at low-density lipoprotein
cholesterol (LDL-C) goal continue to be at risk for cardiovascu-
lar disease (CVD) events; treating multiple lipid targets, such as
high density lipoprotein cholesterol and triglycerides may result
in further CVD risk reduction. The annual cost per patient
treated to LDL-C goal (<100 mg/dL) with a statin ranges from
$1343–$3025. Niaspan® and Zetia® are two add-on therapies
used in statin-treated patients. A cost-effectiveness analysis was
conducted to estimate the incremental cost of simultaneously
achieving multiple lipid targets with Niaspan versus Zetia.
METHODS: A model was used to predict changes in lipid levels
(total-C, LDL-C, HDL-C, and TG) and associated costs over 1
year among hypothetical cohort of 1000 statin-treated patients
with a history of CVD in a US managed care population. Baseline
CVD risk factors and lipid parameters, along with their distri-
butions, were based on NHANES data Efﬁcacy was based on
product labeling, and adjusted to reﬂect mean days with combi-
nation therapy on-hand per published studies. Prices were based
on wholesale acquisition costs (WAC); daily WAC for Niaspan
was weighted to reﬂect a 12-week dose-titration period.
RESULTS: When combined with simvastatin, Crestor®,
Lipitor®, or Pravachol® the percentage of statin patients attain-
ing three lipid targets was higher for Niaspan in comparison to
Zetia (range, 98%–100% versus 87%–95%, respectively).
Annualized per patient treatment costs for Zetia were lower than
Niaspan (difference, range: $3–$77). Niaspan had the lowest
annualized cost per patient attaining three lipid targets compared
to Zetia (range, $681–$1379 versus $681–$1441, respectively).
The incremental cost of one additional patient attaining three
lipid targets with Niaspan over Zetia, ranged from $59–$678.
CONCLUSIONS: The addition of Niaspan relative to Zetia in
patients receiving on-going statin therapy results in more patients
attaining three lipid targets and the cost per patient attaining
three lipid targets is lower.
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OBJECTIVES: To evaluate costs and beneﬁts of diagnosing
patients of syncope with unknown aetiology with standard of
care or with implanted loop recorders in Spain. METHODS:
Syncope is a recurrent and unpredictable symptom. It accounts
for 6% of hospitalisations and nearly a third of syncope cases
remain of unknown etiology after the initial testing. We have
evaluated the direct health care costs and diagnostic yield of a
conventional diagnosis pathway and compared them with a
strategy that includes a subcutaneous device for the diagnosis of
syncope (Reveal DX®) in the Spanish context. An economic
model was built to analyze the diagnosis yield of Reveal DX®,
and costs of both diagnostic strategies. It was based on a clinical
trial approach, the Eastbourne Syncope Assessment Study
(Farwell, 2006). We used 2007 updated Spanish Cost data from
the literature. RESULTS: Reveal DX with an ICER per additional
diagnosis made of 2186€ (95% CI €1761–€5041) is cost effective
in Spain. The ICER Conﬁdence Interval (CI), was calculated with
Probabilistic Sensitivity Analysis to account for the variability of
medical resources, unit costs and diagnostic yield. CONCLU-
SIONS: Introducing Reveal DX® in the diagnosis of syncope of
unknown etiology in Spain is a cost effective strategy since it
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OBJECTIVES: Cardiovascular diseases result in an enormous
burden to society. Therefore, early identiﬁcation of and pharma-
cotherapeutic intervention in subjects at risk for cardiovascular
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